Alan Friedman
Affiliations: | University of Texas at Austin, Austin, Texas, U.S.A. |
Area:
Modern Literature, American Literature, English LiteratureGoogle:
"Alan Friedman"Children
Sign in to add trainee| Samuel S. Kinch | grad student | 2001 | UT Austin |
| Christopher D. Chung | grad student | 2008 | UT Austin |
| James R. Jesson | grad student | 2010 | UT Austin |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Fleischmann R, Friedman A, Drescher E, et al. (2022) Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial. The Lancet. Rheumatology. 4: e395-e406 |
| Strand V, Tundia N, Wells A, et al. (2020) Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY. Rheumatology (Oxford, England) |
| Edwards CJ, Sawant R, Garg V, et al. (2020) A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis. Rheumatology and Therapy |
| Takeuchi T, Rischmueller M, Blanco R, et al. (2020) Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: A sub-analysis of the Phase 3 SELECT-EARLY study. Modern Rheumatology. 1-22 |
| van Vollenhoven R, Takeuchi T, Pangan AL, et al. (2020) Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Randomized, Double-blind, Active-comparator, Multi-center, Multi-country Trial. Arthritis & Rheumatology (Hoboken, N.J.) |
| Peterfy C, Strand V, Genovese MC, et al. (2020) Thu0211 Radiographic Outcomes In Patients With Rheumatoid Arthritis Receiving Upadacitinib As Monotherapy Or In Combination With Methotrexate: Results At 2 Years From The Select-Compare And Select-Early Studies Annals of the Rheumatic Diseases. 79: 330-331 |
| Vollenhoven RV, Takeuchi T, Rischmueller M, et al. (2020) Thu0217 Upadacitinib Monotherapy In Methotrexate-Naïve Patients With Rheumatoid Arthritis: Results At 72 Weeks From Select-Early Annals of the Rheumatic Diseases. 79: 334-335 |
| Kapetanovic MC, Andersson M, Friedman A, et al. (2020) Sat0145 Efficacy And Safety Of Upadacitinib Monotherapy In Mtx-Naïve Patients With Early Active Ra Receiving Treatment Within 3 Months Of Diagnosis: A Post-Hoc Analysis Of The Select-Early Annals of the Rheumatic Diseases. 79: 1011-1011 |
| Peterfy C, Genovese MC, Song I, et al. (2020) P225 Inhibition of structural joint damage with upadacitinib as monotherapy or in combination with MTX in patrients with RA: one-year outcomes from the select Phase 3 programme Rheumatology. 59 |
| Edwards C, Sawant R, Du EX, et al. (2020) P224 A matching-adjusted indirect comparison (MAIC) of upadacitinib versus tofacitinib in csDMARD-IR patients with moderate to severe RA Rheumatology. 59 |